Mangoceuticals, Inc. MGRX
Set alert
0.23 USD -0.01 -2.31%
At close · Nov 2
0.23 0.00 +0.48%
After hours · Nov 2, 5:19 PM ET
0.2245 Day range 0.2424
0.162 52-week range 2.41
- YTD
- -69.19%
- 1 year
- -89.04%
- Open
- 0.2375
- Prev close
- 0.2334
- Mkt cap
- 5.07M
- Vol
- 439.35K
- Avg vol
- 3.54M
- EPS
- -1.02
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.2245
- High
- 0.2424
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.21
- Inst. own
- 4.69%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.49
- 200-d avg
- 3.94
- 1y target
- 0.00
6M chart
Signals (56)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 22, 2026 | 1 week ago |
| SMA: Bearish | Oct 9, 2026 | 3 weeks ago |
| MACD: Sell Signal | Oct 8, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 7, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 6, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 6, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 5, 2026 | 4 weeks ago |
| SMA: Bearish | Oct 2, 2026 | 1 month ago |
| SMA: Bullish | Oct 1, 2026 | 1 month ago |
| SMA: Bullish | Sep 29, 2026 | 1 month ago |
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| SMA: Bullish | Sep 24, 2026 | 1 month ago |
| SMA: Bearish | Sep 22, 2026 | 1 month ago |
| SMA: Bullish | Sep 18, 2026 | 1 month ago |
| SMA: Bearish | Sep 17, 2026 | 1 month ago |
| SMA: Bullish | Sep 16, 2026 | 1 month ago |
| SMA: Bullish | Sep 15, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 11, 2026 | 1 month ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| SMA: Bullish | Aug 21, 2026 | 2 months ago |
| SMA: Bearish | Aug 20, 2026 | 2 months ago |
| SMA: Bearish | Aug 19, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 17, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 10, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 4, 2026 | 3 months ago |
| SMA: Bullish | Jul 31, 2026 | 3 months ago |
| SMA: Bullish | Jul 31, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 31, 2026 | 3 months ago |
| SMA: Bearish | Jul 30, 2026 | 3 months ago |
| SMA: Bearish | Jul 30, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 30, 2026 | 3 months ago |
| RSI: Overbought | Jul 23, 2026 | 3 months ago |
| SMA: Bullish | Jul 17, 2026 | 3 months ago |
| SMA: Bullish | Jul 16, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 16, 2026 | 3 months ago |
| SMA: Bearish | Jul 15, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 15, 2026 | 3 months ago |
| SMA: Bullish | Jul 14, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 14, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 13, 2026 | 3 months ago |
| SMA: Bearish | Jul 7, 2026 | 3 months ago |
| SMA: Bearish | Jul 7, 2026 | 3 months ago |
| SMA: Bullish | Jul 1, 2026 | 4 months ago |
| SMA: Bullish | Jul 1, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 26, 2026 | 4 months ago |
| SMA: Bearish | Jun 2, 2026 | 5 months ago |
| MACD: Sell Signal | Jun 2, 2026 | 5 months ago |
| SMA: Bearish | May 29, 2026 | 5 months ago |
| SMA: Bullish | May 22, 2026 | 5 months ago |
| SMA: Bullish | May 14, 2026 | 5 months ago |
| MACD: Buy Signal | May 14, 2026 | 5 months ago |
| MACD: Sell Signal | May 13, 2026 | 5 months ago |
| SMA: Bearish | May 12, 2026 | 5 months ago |
| MACD: Buy Signal | May 11, 2026 | 5 months ago |
| SMA: Bullish | May 8, 2026 | 5 months ago |
Key statistics
- Market cap
- 6.17M
- Enterprise value
- 4.40M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 7.11
- Price / book
- 4.57
- EPS (TTM)
- -5.70
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 866.79K
- Revenue growth
- 15.50%
- Free cash flow
- -2.16M
- Total cash
- 490.24K
- Total debt
- 285.05K
- Return on equity
- -108.44%
- Shares outstanding
- 2.49M
- Short % of float
- 9.99%
- 50-day average
- 2.49
- 200-day average
- 3.94
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
MGRX Revenue — quarterly 68.76K
MGRX Net income — quarterly -1.31M
MGRX EPS — quarterly -0.09
About Mangoceuticals, Inc.
Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.
- Sector
- Healthcare
- Industry
- Health Information Services
- Country
- United States
- Website
- mangoceuticals.com
News
- Analyzing Mangoceuticals (NASDAQ:MGRX) & Quest Diagnostics (NYSE:DGX)
- Mangoceuticals (NASDAQ: MGRX) closes 74% premium stock sale with warrants
- Mangoceuticals Closes Registered Direct Offering Following $2.5M Strategic Investment Commitment In MangoRx IP Holdings To Support Intellectual Property Commercialization
- Mangoceuticals Closes Registered Direct Offering Priced at 74% Premium to Recent Market Close
- Stock Market Today: S&P 500, Dow Jones Futures Gain as September Jobs Report Misses Expectations— Nike, Synaptics, Corteva in Focus (UPDATED)
- Nike Posts Mixed Q1 Results, Joins Mangoceuticals And Other Big Stocks Moving Lower In Friday's Pre-Market Session
- Nike Posts Mixed Q1 Results, Joins Mangoceuticals And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
- Nike, Synaptics And 3 Stocks To Watch Heading Into Friday
- Mangoceuticals (MGRX) Shares Fall 12% After Hours: Here's Why
- Mangoceuticals’ MangoRx IP Secures $2.5M Investment From Strategic Investors, Receives Initial $1.75M Tranche
Your note
Sign in to keep a note on MGRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COHEN JACOB D. | Chief Executive Officer | Stock Gift | Aug 25, 2024 | 0 |
| D'ALESSIO LORRAINE PAMELA | Director | Stock Award(Grant) | Jun 2, 2024 | 175,000 |
| HAMILTON ALEX P | Director | Sale | Jun 25, 2024 | 50,000 |
| HAMMER AMANDA ELIZABETH | Chief Operating Officer | Stock Award(Grant) | Jun 2, 2024 | 175,000 |
| JOHNSTON EUGENE M | Chief Financial Officer | Stock Award(Grant) | Oct 2, 2023 | 200,000 |
| MYERS KENNY | Director | Stock Award(Grant) | Jun 2, 2024 | 175,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Ackerman Capital Advisors, LLC | 2.34% | 58,224 | 144.40K | Sep 29, 2024 |
| Captrust Financial Advisors | 0.69% | 17,077 | 42.35K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.35% | 8,755 | 21.71K | Sep 29, 2024 |
| Peak6 Investments Llc | 0.24% | 5,884 | 14.59K | Sep 29, 2024 |
| McCollum Christoferson Group LLC | 0.23% | 5,720 | 14.19K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.10% | 2,523 | 6.26K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.27% | 6,603 | 16.38K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.13% | 3,245 | 8.05K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.06% | 1,577 | 3.91K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.02% | 452 | 1.12K | Oct 30, 2024 |